Home Tags Monomethyl auristatin E

Tag: monomethyl auristatin E

Seattle Genetics to Co-develop Tisotumab Vedodin with Genmab for the Treatment...

Genmab, an international biotechnology company headquartered in Copenhagen, Denmark, and Seattle Genetics, confirmed that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The...

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...

Phase II Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory...

Positive, mature, results from a Phase II study of glembatumumab vedotin (Celldex Therapeutics) in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK...

PepTalk 2017: Translating Toxicology Data from Non-human Species to the Clinical...

The need to improve the translation of risk between adverse events in non-human species and the clinical population was a topic addressed by several...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

Glembatumumab vedotin Shows Encouraging anti-tumor Activity Checkpoint Inhibitor-refractory Metastatic Melanoma

Results from a phase II trial presented in a poster at the annual meeting of the European Society of Medical Oncology, held in Copenhagen,...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

Bayer uses Progenics’ PSMA Antibody Technology for the Development of Alpha-Radiolabeled...

Progenics Pharmaceuticals, Inc. (Tarrytown, NY), has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Progenics's prostate specific...

Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...

During the annual meeting of the American Association for Cancer Research (AACR) being held  April 16 - 20, 2016 in New Orleans, LA, Celldex...

Glembatumumab Vedotin in Patients with Metastatic gpNMB-overexpressing Triple-negative Breast Cancer

Researchers have, in the last decades, made major advances in the development of therapies for breast cancer by identifying key markers known to drive...

Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

X